Moreover, it would be of interest to assess more precisely circulating PCPE-1 levels in NASH patients with various degrees of fibrosis (as reported by Gokce and colleagues [24] in patients suffering from chronic hepatitis B) to determine whether PCPE-1 could be a diagnostic biomarker or be used to monitor efficacy of anti-fibrotic drugs. The gene discussed is PCOLCE; the disease is metabolic dysfunction-associated steatohepatitis.